Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
Day One Biopharmaceuticals (Nasdaq: DAWN) will report its third quarter 2025 financial results on Tuesday, November 4, 2025.
The company will host a live conference call and webcast on Nov. 4, 2025 at 4:30 p.m. ET to discuss results and corporate progress. Live audio will be available in the Events section of Day One's Media & Investors page, and an archived replay will be accessible for 30 days after the event.
Day One Biopharmaceuticals (Nasdaq: DAWN) renderà noti i propri risultati finanziari del terzo trimestre 2025 martedì 4 novembre 2025.
L'azienda terrà una conference call in diretta e una webcast martedì 4 novembre 2025 alle 16:30 ET per discutere i risultati e i progressi aziendali. L'audio in diretta sarà disponibile nella sezione Eventi della pagina Media & Investors di Day One, e una replica registrata sarà accessibile per 30 giorni dopo l'evento.
Day One Biopharmaceuticals (Nasdaq: DAWN) informará sus resultados financieros del tercer trimestre de 2025 el martes 4 de noviembre de 2025.
La empresa organizará una llamada de conferencia en vivo y una transmisión web el 4 de noviembre de 2025 a las 16:30 ET para discutir los resultados y el progreso corporativo. La transmisión de audio en vivo estará disponible en la sección de Eventos de la página de Medios e Inversores de Day One, y una reproducción archivada estará accesible durante 30 días después del evento.
Day One Biopharmaceuticals (Nasdaq: DAWN) 는 2025년 3분기 재무 결과를 2025년 11월 4일 화요일에 발표합니다.
회사는 2025년 11월 4일 오후 4시 30분(Eastern Time)에 라이브 컨퍼런스 콜 및 웹캐스트를 개최하여 결과와 기업 진행 상황을 논의할 예정입니다. 라이브 오디오는 Day One의 미디어 & 투자자 페이지의 이벤트 섹션에서 이용 가능하며, 이벤트 종료 후 30일 동안 아카이브 재생이 제공됩니다.
Day One Biopharmaceuticals (Nasdaq: DAWN) publiera ses résultats financiers du troisième trimestre 2025 le mardi 4 novembre 2025.
L'entreprise tiendra une conférence téléphonique en direct et une diffusion Web le 4 novembre 2025 à 16 h 30 ET pour discuter des résultats et des progrès de l'entreprise. L'audio en direct sera disponible dans la section Événements de la page Médias et Investisseurs de Day One, et une réplique enregistrée sera accessible pendant 30 jours après l'événement.
Day One Biopharmaceuticals (Nasdaq: DAWN) wird seine Finanzergebnisse des dritten Quartals 2025 am Dienstag, den 4. November 2025 bekannt geben.
Das Unternehmen wird am 4. November 2025 um 16:30 Uhr ET eine Live-Konferenzschaltung und einen Webcast abhalten, um Ergebnisse und Unternehmensfortschritte zu besprechen. Live-Audio steht im Bereich Veranstaltungen der Day One-Medien- & Investorenseite zur Verfügung, und eine archivierte Wiedergabe ist 30 Tage nach der Veranstaltung zugänglich.
Day One Biopharmaceuticals (Nasdaq: DAWN) ستعلن عن نتائجها المالية للربع الثالث من عام 2025 يوم الثلاثاء 4 نوفمبر 2025. ستستضيف الشركة مكالمة مؤتمرات حية وبثاً مباشراً عبر الويب في 4 نوفمبر 2025 الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة لمناقشة النتائج والتقدم المؤسسي. سيكون الصوت المباشر متاحاً في قسم الأحداث من صفحة Day One الإعلامية للمستثمرين، وسيكون تشغيل إعادة أرشيفية متاحاً لمدة 30 يوماً بعد الحدث.
Day One Biopharmaceuticals(纳斯达克:DAWN) 将于 2025 年 11 月 4 日星期二公布其 2025 年第三季度财务业绩。
公司将于 2025 年 11 月 4 日东部时间 16:30 举行现场电话会议和网络直播,以讨论业绩和公司进展。现场音频将在 Day One 的媒体与投资者页面的事件部分提供,活动结束后 30 天 内可访问存档回放。
- None.
- None.
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2025.
Live audio of the webcast will be accessible in the Events section of Day One’s Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days following the event.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer – regardless of age – starting from day one.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™) and DAY301.
Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
